These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18064346)

  • 41. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
    Thachil J
    Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Delayed-type hypersensitivity to heparin: diagnosis and therapeutic management].
    Nosbaum A; Pralong P; Rozieres A; Dargaud Y; Nicolas JF; Bérard F
    Ann Dermatol Venereol; 2012 May; 139(5):363-8. PubMed ID: 22578340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Perioperative bridging with fondaparinux in a woman with antithrombin deficiency.
    Bauersachs R; Alban S
    Thromb Haemost; 2007 Mar; 97(3):498-9. PubMed ID: 17334522
    [No Abstract]   [Full Text] [Related]  

  • 44. Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.
    Schindewolf M; Steindl J; Beyer-Westendorf J; Schellong S; Dohmen PM; Brachmann J; Madlener K; Pötzsch B; Klamroth R; Hankowitz J; Banik N; Eberle S; Müller MM; Kropff S; Lindhoff-Last E
    J Am Coll Cardiol; 2017 Nov; 70(21):2636-2648. PubMed ID: 29169470
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of Fondaparinux Versus Nadroparin Calcium Thromboprophylaxis on Clinical Parameters Following Total Knee Arthroplasty.
    Mihaljević Z; Dimnjaković D; Tripković B; Buljan M; Aljinović A; Delimar D; Bićanić G
    Acta Clin Croat; 2016 Sep; 55(3):414-421. PubMed ID: 29045105
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tolerance to intravenous administration of heparin and heparinoid in a patient with delayed-type hypersensitivity to heparins and heparinoids.
    Boehncke WH; Weber L; Gall H
    Contact Dermatitis; 1996 Aug; 35(2):73-5. PubMed ID: 8917822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.
    Agnelli G; Bergqvist D; Cohen AT; Gallus AS; Gent M;
    Br J Surg; 2005 Oct; 92(10):1212-20. PubMed ID: 16175516
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Use of low molecular weight heparins].
    Llau JV; Hoyas L; Ezpeleta J; García-Polit J
    Rev Esp Anestesiol Reanim; 1997 Feb; 44(2):88-9. PubMed ID: 9148365
    [No Abstract]   [Full Text] [Related]  

  • 49. Home therapy with LMWH in deep vein thrombosis: randomized study comparing single and double daily administrations.
    Bellosta R; Ferrari P; Luzzani L; Carugati C; Cossu L; Talarico M; Sarcina A
    Angiology; 2007; 58(3):316-22. PubMed ID: 17626986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Delayed hypersensitivity challenged by subcutaneous Bemiparin.
    Moreno Escobosa MC; Moya Quesada MC; Granados SC; Amat López J
    Allergol Immunopathol (Madr); 2011; 39(5):309-10. PubMed ID: 21129837
    [No Abstract]   [Full Text] [Related]  

  • 51. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight.
    Grims RH; Weger W; Reiter H; Arbab E; Kränke B; Aberer W
    Br J Dermatol; 2007 Sep; 157(3):514-7. PubMed ID: 17573880
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An unusual adverse effect of nadroparin injections: Calcinosis cutis.
    Nuno-Gonzalez A; Calzado-Villarreal L; Gutierrez-Pascual M; Gamo-Villegas R; Sanz-Robles H; Sanchez-Gilo A; Pinedo-Moraleda F; Lopez-Estebaranz JL
    Dermatol Online J; 2011 Nov; 17(11):4. PubMed ID: 22136860
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current options in the prevention of thromboembolic disease.
    Ansell J; Bergqvist D
    Drugs; 2004; 64 Suppl 1():1-5. PubMed ID: 15586622
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Once-daily fondaparinux monotherapy without warfarin for long-term treatment of venous thromboembolism.
    Shetty R; Seddighzadeh A; Parasuraman S; Vallurupalli NG; Gerhard-Herman M; Goldhaber SZ
    Thromb Haemost; 2007 Dec; 98(6):1384-6. PubMed ID: 18064344
    [No Abstract]   [Full Text] [Related]  

  • 55. Fondaparinux, the first selective factor Xa inhibitor.
    Turpie AG; Eriksson BI; Lassen MR; Bauer KA
    Curr Opin Hematol; 2003 Sep; 10(5):327-32. PubMed ID: 12913785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fondaparinux versus nadroparin for thromboprophylaxis following minimally invasive esophagectomy: A randomized controlled trial.
    Song J; Xuan L; Wu W; Shen Y; Tan L; Zhong M
    Thromb Res; 2018 Jun; 166():22-27. PubMed ID: 29653390
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Study of tolerance].
    Forette B; Wolmark Y
    Presse Med; 1995 Mar; 24(12):567-71. PubMed ID: 7770402
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Eczematous infiltrated plaques to subcutaneous heparin: a type IV allergic reaction.
    Bircher AJ; Flückiger R; Buchner SA
    Br J Dermatol; 1990 Oct; 123(4):507-14. PubMed ID: 2151304
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of low molecular weight heparin on survival in patients with advanced malignancy.
    Klerk CP; Smorenburg SM; Otten HM; Lensing AW; Prins MH; Piovella F; Prandoni P; Bos MM; Richel DJ; van Tienhoven G; Büller HR
    J Clin Oncol; 2005 Apr; 23(10):2130-5. PubMed ID: 15699479
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acute generalized exanthematous pustulosis from dalteparin.
    Komericki P; Grims R; Kränke B; Aberer W
    J Am Acad Dermatol; 2007 Oct; 57(4):718-21. PubMed ID: 17610994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.